# GEA Enzymes

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gea-enzymes

- Industry: Biotechnology
- Headquarters: Sunnyvale, US
- Website: www.geaenzymes.com
- Latest round: Seed (Jan 19, 2018)
- Investors on record: 2

## About

GEA Enzymes develops advanced technological solutions focused on improving operational efficiency and process automation across various industries, providing software tools for data management and client interaction.Founded in 2015 by Leonardo Alvarez in Sunnyvale, US, GEA Enzymes specializes in innovative software solutions for operational efficiency. The company has successfully completed 6 deals, with its most recent funding round being a Seed round on January 19, 2018, where it raised USD 100,000, the total amount raised also being USD 100,000.GEA Enzymes offers a suite of technology solutions designed to enhance operational efficiency and streamline processes across multiple sectors, including finance, healthcare, and retail. Their core offerings consist of a comprehensive software platform for data analytics, workflow automation, and customer relationship management, tailored to address challenges like data silos and regulatory compliance. Their products are utilized by a diverse clientele, ranging from small and medium-sized enterprises to large corporations, across markets in North America, Europe, and parts of Asia.The company earns revenue primarily through a subscription-based model, granting clients ongoing access to its software solutions. This model fosters long-term client relationships while ensuring continuous updates and support. Additional revenue is generated through strategic partnerships with other technology firms, allowing GEA Enzymes to offer integrated client solutions. The pricing structure accommodates various business sizes, with premium pricing on flagship products reflecting their advanced capabilities. Professional services such as training and consulting also contribute to revenue, ensuring clients maximize their investment in the company's technology.GEA Enzymes aims to expand its product offerings with upcoming innovations planned for release in the next year, targeting improvements in data analytics capabilities. The company is also looking to penetrate new geographic markets, specifically targeting regions in Asia and Europe for expansion by 2023. The funding raised in January 2018 from IndieBio and SOSV will be utilized to support these growth initiatives, enabling the company to enhance its product portfolio and market outreach.

## Funding rounds

- Seed, Jan 19, 2018 — SOSV, IndieBio

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed
- IndieBio (https://capitalatlas.ai/funds/indiebio) — Seed